Proteostasis Failure in Aging Skeletal Muscle Fuels Sarcopenia
Aging skeletal muscle loses more than mass; it loses the machinery that keeps proteins functional. In sarcopenia and other forms of muscle wasting, the proteostasis network no longer clears damaged proteins with the same efficiency, and that failure allows misfolded and aggregation-prone proteins to accumulate inside the fiber. Protein quality control depends on a tightly coordinated balance between synthesis, repair, folding, trafficking, and degradation. When that balance tips, muscle tissue becomes less able to maintain contractile strength, recover from stress, or resist the catabolic pressures that accompany aging and chronic disease.
The biology is not abstract. A decline in protein synthesis, increased proteolytic activity, and sustained endoplasmic reticulum stress push skeletal muscle toward net protein loss. Over time, this creates a structural and metabolic environment in which atrophy becomes self-reinforcing. Fibers shrink, function erodes, and the clinical consequences extend beyond weakness to falls, frailty, disability, and worse survival in vulnerable older adults.
Protein Quality Control Breaks Down at Multiple Levels
The proteostasis network operates through several interconnected systems, and aging disrupts more than one node at a time. The ubiquitin proteasome system tags damaged proteins for degradation, the autophagy lysosomal pathway clears larger cellular debris and dysfunctional organelles, and the unfolded protein response attempts to restore endoplasmic reticulum balance when misfolded proteins build up. In healthy muscle, these pathways cooperate to preserve myofiber integrity. In aged muscle, each pathway may become blunted, overactivated, or chronically stressed, depending on the catabolic context.
The review places protein loss from synthesis-degradation imbalance at the center of muscle atrophy. Once anabolic signaling weakens and proteolytic pathways dominate, the muscle cell begins to consume its own structural components faster than it can rebuild them. That shift is especially important in aging, where the reserve capacity to adapt to stress is already reduced. The result is not a single lesion but a layered breakdown of quality control systems that normally keep skeletal muscle resilient.
Endoplasmic Reticulum Stress and Catabolic Signaling Keep the Muscle in Decline
Endoplasmic reticulum stress is a recurring feature of the wasting state because protein folding demands rise while folding capacity falls. Misfolded proteins accumulate, the unfolded protein response is activated, and the cell shifts toward emergency management rather than growth and repair. If this response remains prolonged, it stops being protective and starts amplifying dysfunction. Chronic stress signaling can reinforce proteolysis, suppress synthesis, and intensify the intracellular environment that favors atrophy.
This helps explain why muscle wasting is so persistent in aging and chronic illness. Skeletal muscle does not fail only because it is old; it fails because the systems that should repair and recycle proteins are no longer synchronized. The biology of the fiber changes from maintenance to attrition, and that transition becomes visible at the bedside as slower gait, reduced reserve, and a narrowed capacity to recover from illness or inactivity.
Aging muscle is not simply underfed or underused; it is biologically mismanaged at the level of protein turnover.
Therapeutic Targets Extend Beyond Muscle Mass Alone
The review discusses experimental and clinical strategies aimed at restoring healthier proteostasis rather than treating atrophy as a purely structural problem. Targeting the ubiquitin proteasome system, autophagy lysosomal pathway, and unfolded protein response offers a mechanistically grounded way to intervene upstream of overt muscle loss. The rationale is straightforward: if protein synthesis can be supported and excess degradation can be restrained or redirected, muscle fibers may retain more of their architecture and function.
The article also points to emerging approaches that could reshape the field. PROTACs may allow more selective protein degradation strategies, while extracellular vesicle-based therapies raise the possibility of intercellular delivery of protective signals. Artificial intelligence-driven predictive models could help identify which patients are most likely to deteriorate, and which biological signatures may respond to targeted interventions. These are not replacements for established care, but they represent a shift toward precision in a condition that has long been treated with broad, nonspecific measures.
Mobility Preservation Depends on Protein Homeostasis
The clinical stakes are high because muscle wasting is not a cosmetic or isolated biochemical issue. It affects mobility, independence, and quality of life, and it contributes to the broader vulnerability of older adults. The review frames mobility preservation as a central therapeutic goal, not an optional outcome. Once muscle strength drops far enough, everyday functions such as standing, walking, climbing stairs, and recovering from intercurrent illness become more precarious.
That makes proteostasis a practical therapeutic target. Interventions that stabilize protein folding and turnover could influence outcomes that matter directly to patients: physical performance, resilience during hospitalization, and the ability to remain independent. The challenge is that aging muscle likely requires interventions that are coordinated rather than single-pathway fixes, because the proteostasis network itself is multisystem and interdependent.
Where the Field Needs to Go Next
The review closes around a clear research need: better therapies that can slow or mitigate age-related deterioration in muscle physiology. Experimental signals are encouraging, but the field still needs stronger translation from mechanistic insight to clinical intervention. Work on muscle wasting will likely depend on defining which component of proteostasis is most actionable in a given patient, whether the dominant issue is impaired folding, inadequate recycling, excessive proteolysis, or unresolved ER stress.
A precision framework may be the most realistic path forward. If predictive models can identify proteostatic failure early, and if targeted therapies can be matched to the dominant pathway disturbance, treatment could move from reactive care to prevention of decline. The remaining uncertainty is not whether proteostasis matters, but which interventions can safely restore it in aging human muscle without disrupting the essential protein turnover that healthy tissue still needs.